October 8, 2015
Recommended Topic Related To:


"The US Food and Drug Administration (FDA) is investigating the "rare but serious" risk for slowed or difficult breathing in children 17 and younger treated with the opioid analgesic tramadol.

"This risk may be increased in children tr"...


Discontinued Warning IconPlease Note: This Brand Name drug is no longer available in the US.
(Generic versions may still be available.)

(1% Sodium Hyaluronate)
Viscoelastic Preparation


PROVISC® (sodium hyaluronate) Viscoelastic Preparation is a sterile, non-pyrogenic, high molecular weight, noninflammatory highly purified fraction of sodium hyaluronate, dissolved in physiological sodium chloride phosphate buffer. Each mL of PROVISC contains active 10.0mg sodium hyaluronate; 0.56mg dibasic sodium phosphate, anhydrous; 0.04mg monobasic sodium phosphate; 8.4mg sodium chloride; hydrochloric acid and/or sodium hydroxide to adjust pH and water for injection.

Last reviewed on RxList: 2/15/2005
This monograph has been modified to include the generic and brand name in many instances.

Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Women's Health

Find out what women really need.